Clinical trials: Post-Operative Prostate Cancer
Prostate Cancer
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in…
- Trial name
- CoSMAP (NCT07666217)
- Where
- 8 sites in Japan
- Volunteers
- 625 people
- Sponsor
- Intuitive Surgical
Prostate Cancer
Multi-site Decision Impact Study for Decipher
This prospectively designed retrospective clinical utility study will evaluate urologists' treatment recommendations before and after reviewing Decipher results for selected patient cases.
- Trial name
- ASSESS-D (NCT02034825)
- Testing
- Decipher Questionnaire
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- GenomeDx Biosciences Corp
Prostate Cancer
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer
RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.
- Trial name
- NCT00336934
- Testing
- pomegranate juice
- Volunteers
- 183 people
- Sponsor
- Roll International Corporation
Prostate Cancer
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
The influence of Decipher test on urologist and patient treatment plan choices immediately post RP and at the time of PSA rise or BCR
- Trial name
- PRO-IMPACT (NCT02080689)
- Testing
- Decipher
- Where
- 19 sites in United States
- Volunteers
- 286 people
- Sponsor
- GenomeDx Biosciences Corp
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
High-risk Prostate Cancer
Immunotherapy Before and After Surgery
This Phase 2 clinical trial is testing a new immunotherapy combination (N-803, ETBX-071, M-CENK) for men with high-risk prostate cancer before and after prostate surgery.
- Trial name
- NCT06765902
- Testing
- N-803, ETBX-071, M-CENK
- Sponsor
- ImmunityBio, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
2 Years PSA Recurrence Rate
Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.
The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The…
- Trial name
- NCT01123434
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- AstraZeneca